Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation.

Nicole P DaukshusAnthony CirincioneMolly SiverSherry MathewBinni KunvarjeeAmelia ChanJaap Jan BoelensSusan K SeoGenovefa A PapanicolaouNancy A Kernan

Published in: Journal of the Pediatric Infectious Diseases Society (2022)

There are limited data for letermovir as primary cytomegalovirus (CMV) prophylaxis in patients less than 18 years of age. We report 9 adolescent patients who received letermovir following hematopoietic cell transplantation. No patients developed clinically significant CMV while taking letermovir. Letermovir was well tolerated and efficacious in preventing CMV infections.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
mental health
epstein barr virus
patient reported outcomes